(3S,10R,13S)-10,13-Dimethyl-17-(trifluoromethylsulfonyloxy)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1Hcyclopenta[a]phenanthren-3-yl 2,2,2-trifluoroacetate;
| Product Name |
(3S,10R,13S)-10,13-Dimethyl-17-(trifluoromethylsulfonyloxy)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1Hcyclopenta[a]phenanthren-3-yl 2,2,2-trifluoroacetate;
|
| Product Code |
DA-A007-17
|
| Chemical name |
(3S,10R,13S)-10,13-Dimethyl-17-(trifluoromethylsulfonyloxy)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1Hcyclopenta[a]phenanthren-3-yl 2,2,2-trifluoroacetate;
|
| Synonyms |
(3S,10R,13S)-10,13-dimethyl-17-(((trifluoromethyl)sulfonyl)oxy)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl 2,2,2-trifluoroacetate;
|
| Impurity |
NA
|
| CAS Number |
1802323-89-2
|
| Alternate CAS # |
NA
|
| Molecular form |
C22H26F6O5S
|
| Appearance |
NA
|
| Melting Point |
NA
|
| Mol. Weight |
516.50
|
| Storage |
2-8°C Refrigerator
|
| Solubility |
NA
|
| Stability |
NA
|
| Category |
pharmaceutical standards,impurities,metabolites,fine chemicals
|
| Boiling Point |
NA
|
| Applications |
(3S,10R,13S)-10,13-dimethyl-17-(trifluoromethylsulfonyloxy)-2,3,4,7,8,9,10,11,12,13,14,15-dodecahydro-1Hcyclopenta[a]phenanthren-3-yl 2,2,2-trifluoroacetate is an impurity of Abiraterone, a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), is currently undergoing phase II clinical trials as a potential drug for the treatment of androgen-dependent prostate cancer. (Abiraterone Impurity 8).
|
| Dangerous Goods Info |
NA
|
| References |
NA
|
| Extra Notes |
NA
|
| Documents (MSDS) |
No Data Available
|
| Keywords |
NA |
